Plastic Waste Rules 2026: What Producers & Importers Must Do Now
India’s PWM Amendment Rules 2026 (G.S.R. 237(E)) impose binding recycled content targets, new importer obligations, and ₹1 crore penalties. Act before June 30.
Regulatory Updates
CDSCO Public Notice on Disposal/Rejection of Long-Pending Applications on SUGAM Portal
he Central Drugs Standard Control Organization (CDSCO) has issued a new public notice dated 4 May 2026 regarding the disposal and rejection of long-pending applications
Regulatory Updates
FSSAI Nutraceuticals Licensing: 2026 Compliance Guide
The March 2026 FSSAI licensing overhaul changes the rules for nutraceutical FBOs — from perpetual validity to new thresholds. Here’s what you must do now.
Regulatory Updates
NDPS Act Compliance for Pharma: Key Updates in 2025–26
India’s NDPS regulatory landscape shifted significantly in late 2025 and early 2026. Here’s what pharmaceutical companies must act on now.
Regulatory Updates
CDSCO Digital Transformation & May 2026 Compliance Deadlines
CDSCO’s unified digital ecosystem launches with May 13 deadline. New AI tools for faster approvals and pending application cleanup underway.
Knowledge Base
BA/BE Studies India: New Prior Intimation System Cuts 90 Days
CDSCO’s March 2026 reforms introduce prior intimation for BA/BE studies, reducing approval times from 90 to 45 days for faster market access.
Knowledge Base
India’s NDCT Amendment Rules 2026: Major Regulatory Overhaul
New rules effective March 7, 2026 cut approval timelines from 90 to 45 days. Prior intimation replaces licenses for low-risk studies.
Regulatory Updates
NDPS Act: Limited 2026 Updates Signal Regulatory Stability
Recent searches reveal minimal NDPS notifications in Q1 2026, while related pharmaceutical regulations show active enforcement. Key compliance insights.
Regulatory Updates
CDSCO New 2026 Rules: Application Rejections & IVD Import Guide
CDSCO threatens rejection of 2+ year pending applications by Feb 14, 2026. New IVD import guidance and cosmetic enforcement actions reshape compliance.
CDSCO Circular (23–24 February 2026)
Key highlights from the CDSCO circular on “Testing of drugs for grant of permissions for import/manufacture of New Drug for sale or for distribution and